Outcomes of various palliative interventions in patients with pulmonary arterial hypertension (PAH)
First author [reference] | Palliative procedure | Study design/sample size | Patient characteristics | Outcomes |
Sandoval [42] | Atrial septostomy | Retrospective n=34 | 85% had IPAH 9% had CTEPH 53% had WHO FC IV 41% had WHO FC III 11 patients received PAH-specific therapy after procedure |
|
Chiu [46] | Atrial septostomy | Retrospective n=32 patients No control group | All patients had PAH 63% had IPAH 78% had WHO FC III/IV All patients were receiving PAH-specific therapy | No significant change in mPAP No significant change in RAP No significant change in BNP |
Chen [44] | PADN | Prospective n=21 13 underwent PADN 8 patients refused PADN and served as control group | All patients had IPAH 13 underwent PADN 8 IPAH patients did not undergo PAH All were on beraprost Mean WHO FC 3.6 | Survival was not assessed Decrease in mPAP and PVR post-PADN Increase in cardiac output post-PADN Improvement in 6MWD and WHO FC |
IPAH: idiopathic pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; WHO: World Health Organization; FC: functional class; 6MWD: 6-min walking distance; mPAP: mean pulmonary artery pressure; RVEDP: right ventricular end-diastolic pressure; LVEDP: left ventricular end-diastolic pressure; RAP: right atrial pressure; BNP: brain natriuretic peptide; PADN: pulmonary artery denervation; PVR: pulmonary vascular resistance.